Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts. Article

Web of Science: 000560368301319
International Collaboration

Cited authors

  • Matrana, Marc Ryan; Tsai, Frank; Cleary, James M.; Satti, Suma; Borazanci, Erkut; Estes, Jacob; Moser, Justin; Khanh Tu Do; Du, Lingling; Sharma, Sunil; Khemka, Vivek; Kolmakov, Valentin; Kawabe, Takumi; Shapiro, Geoffrey

Authors

Publication date

  • 2020

Published in

International Standard Serial Number (ISSN)

  • 0732-183X

Volume

  • 38

Issue

  • 15